Skip to main content

Table 1 Baseline clinical characteristics of the 821 patients with locally advanced nasopharynx of head and neck cancer

From: Improving on-treatment risk stratification of cancer patients with refined response classification and integration of circulating tumor DNA kinetics

Characteristics No. of patients (%)
Age, years
 <45 477 (58.1)
 ≥45 344 (41.9)
Sex
 Male 617 (75.2)
 Female 204 (24.8)
Histology, WHO typea
 II 14 (1.7)
 III 807 (98.3)
Smoking
 No 514 (62.6)
 Yes 307 (37.4)
Alcohol
 No 695 (84.7)
 Yes 126 (15.3)
Clinical stageb
 III 350 (42.6)
 IV 471 (57.4)
T stageb
 T1 48 (5.8)
 T2 71 (8.6)
 T3 388 (47.3)
 T4 314 (38.2)
N stageb
 N0 36 (4.4)
 N1 311 (37.9)
 N2 261 (31.8)
N3 213 (25.9)
NAC regimens
 TPF 501 (61.0)
 TP 194 (23.6)
 GP 54 (6.6)
 PF 61 (7.4)
 Othersc 11 (1.3)
NAC cycles
 2 cycles 393 (47.9)
 3 cycles 392 (47.7)
 4 cycles 36 (4.4)
  1. Abbreviations: GP Gemcitabine and cisplatin, N Node, NAC Neoadjuvant chemotherapy, PF Cisplatin and 5-fluorouracil, T Tumor, TP Docetaxel and cisplatin, TPF Docetaxel, cisplatin, and 5-fluorouracil, WHO World Health Organization
  2. aWHO Type II refers to the differentiated non-keratinizing carcinoma; WHO Type III refers to the undifferentiated non-keratinizing carcinoma
  3. bAccording to the 8th edition of the AJCC/UICC Staging System
  4. cOthers included patients with alteration of NAC regimens, for example switch from TPF to GP due to adverse events